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Background. Primary pulmonary hypertension can lead to hypertrophy of the right
ventricle and ultimately to its insufficiency. Lung transplantation remains the only viable
treatment for patients with certain forms of this disease. Usage of extracorporeal mem-
brane oxygenation in veno-arterial form (VA-ECMO) after transplantation is both
protective for left ventricle (enables adaptation to increased blood flow) and right
ventricle (provides time to return to appropriate dimensions and in some cases to
correct tricuspid regurgitaion).
Case Presentation. The case study describes 4 patients who were treated with
VA-ECMO as a perioperative support. Three patients were diagnosed with idiopathic form
of precapillary primary pulmonary hypertension. A fourth patient was a 49-year old woman
diagnosed with hypoplastic pulmonary veins representing the postcapillary form of
pulmonary hypertension. In all of the cases, VA-ECMO was introduced during the
surgery (femoral vein/internal jugular vein and femoral artery) and maintained for
several days after the transplantation. Regular echocardiographic and biochemical
assessment in postoperative course revealed that cardiac function improved during and
after such treatment among all patients. They were successfully weaned off ECMO and
finally surgically explanted without any local complications. One patient was treated with
awake ECMO protocol.
Conclusions. VA-ECMO was proved to be a useful tool during the transplantation and
postoperative period. It helps to restore proper cardiac function, as well as prevent adverse
effects of aforementioned pathologic changes of a heart.*Address correspondence to Magdalena Latos MD, Medical
University of Silesia, Silesian Centre for Heart Diseases ul. Marii
Skłodowskiej-Curie 9 Pawilon C, 41-800 Zabrze, Poland. Tel:
þ48667288893. E-mail: latos.magdalena93@gmail.comPATIENTS suffering from an idiopathic form of pul-monary hypertension usually have an estimated 5-year
survival of 57% [1]. Even though tremendous improvements
have been achieved with pharmacologic therapy, the ma-
jority of patients will require lung transplantation, as it has
been proved to be a higher up-front surgical-risk procedure
to perform, but with excellent long-term survival and quality
of life [2e4]. Significantly increased pulmonary artery pres-
sure leads to a series of pathomorphological and functional
changes in the heart. Poor outcome of idiopathic pulmonary
arterial hypertension patients who have not undergone lungAuthors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
enue, New York, NY 10169
ion Proceedings, 52, 2113e2117 (2020)transplantation has been associated with high right atrial
pressure, low cardiac index, and low venous saturation of
oxygen [5]. If changes of the cardiac muscle are deemed
reversible, lung transplantation can provide great long-term
survival provided proper postoperative management is0041-1345/20
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plantation is particularly important, as certain pathophysi-
ological changes must be diminished. Right ventricular
hypertrophy with impaired systolic function can lead to right
ventricle outflow tract obstruction despite proper fluid
repletion. Sudden increase in the left ventricular cardiac
output is to be expected, as pulmonary circulation regains
proper vessels with low resistance by means of trans-
plantation. However, as the left ventricle was not required
to work with such preload for a long period of time before
transplantation, it will certainly be dysfunctional after
restoration of the proper pulmonary circulation [6]. All
those things can lead to pulmonary edema and primary
graft dysfunction unless, proper conditioning of the heart is
implemented. Such thing can be achieved by concomitant
intra- and postoperative use of veno-arterial mode of
extracorporeal membrane oxygenation (VA-ECMO) [7].
Intraoperative use of this method was described to provide
great results [8,9]. It is also reported that intraoperative use
of this device is superior to standard cardiopulmonary
bypass [8]. What is more, it was proved that this kind
of intraoperative cardiac support presents decreased mor-
tality of the patients when compared with transplantation
without any extracorporeal support in this particular
underlying disease [10]. What is even more important,
prophylactic use of VA-ECMO in the postoperative period
is associated with decreased mortality and favorable long-
term results [8e13]. This type of treatment was originally
proposed by lung transplant centers of Vienna [8,10e12] and
Hannover [9,13] and then introduced into our practice. We
present initial results of the first Polish experience with this
method.
CASE PRESENTATION
This study presents 4 patients with primary pulmonary hyperten-
sion. Three patients received double lung transplantations owing
to idiopathic pulmonary arterial hypertension. Remaining patient
underwent double lung transplantation owing to congenital hypo-
plasia of pulmonary veins. Among all recipients except patient 3,
VA-ECMO was established in the same manner: outflow cannula
(venous) was inserted through femoral vein whereas inflow can-
nula (arterial) was introduced by femoral artery. Peripheral leg
perfusion with additional arterial cannula of the lower limb was
also implemented as a bypass from arterial cannula to distal part
of femoral artery. In case of the first 3 patients, sedation and
mechanical ventilation after procedure was maintained for 2 to 3
days during VA-ECMO therapy. Proper fluid repletion, hemostatic
control aiming at ACT of 160 to 180 seconds, constant supervision
of red blood cells and platelets count (aiming at hematocrit
exceeding 35% and platelet count exceeding 100,000 /mL at all
times), were crucial during the ECMO treatment.
Patient Number 1
A 48-year-old woman was qualified to be a double lung recipient
owing to primary pulmonary hypertension in the course of
congenital hypoplasia of the pulmonary veins. Her medical history
was significant as she underwent 2 thromboembolic incidents (lower
extremity deep vein thrombosis and pulmonary veins thrombosis),as well as such were present among multiple members of her family.
Despite pharmacologic treatment, her postcapillary pulmonary hy-
pertension caused a development of right ventricle heart failure. At
qualification process, transthoracic echocardiography revealed
paradoxical movement of the interventricular septum, right
ventricle systolic pressure (RVSP) at 63 mm Hg, tricuspid valve
regurgitation, and acceleration time (AcT) of 72 ms. Her right heart
catheterization revealed the following: pulmonary artery pressure
59/22/37 mm Hg, mean pulmonary capillary wedge pressure of 23
mm Hg, and pulmonary vascular resistance 3.2 Wood units. She
underwent double lung transplantation without any complications.
The patient was admitted into the intensive care unit (ICU)
sedated, mechanically ventilated, and on VA-ECMO with pump
flow support of 3.6 L/min (80% of cardiac output). Twenty-four
hours after procedure, ECMO flow was constantly being reduced
0.5l/min every 12 hours as permitted by daily evaluations done
during routine echocardiography. ECMO was explanted 3 days af-
ter lung transplantation. Full mental capacity was restored 3 days
after final weaning off. Three days of such treatment temporarily
took a toll on her mental status. Even though she was conscious, it
was difficult for her to initiate and maintain verbal contact, as well
as her allopsychiatric orientation was disturbed. We assume that
constant blood flow provided by ECMO combined with full seda-
tion for several days do not work in the patient’s favor. The patient’s
heart was assessed daily after explantation of VA-ECMO. Three
weeks after such treatment, echocardiography was performed in
order to assess the cardiac function. Previously described mild
tricuspid valve regurgitation subsided. Ejection fraction of the left
ventricle (LVEF) was 56% and it was comparable with preoperative
echocardiographic assessment. Overall cardiac function was
assessed as proper. She was discharged in general good condition.
The patient still remains under care of our facility and so far has
reached 12-month survival.
Patient Number 2
A 39-year-old woman with advanced form of idiopathic pulmonary
arterial hypertension was qualified to be treated by means of lung
transplantation. At qualification her mean pulmonary artery
pressure during right heart catheterization was 57.3 mm Hg,
despite pharmacologic treatment consisting of maximal tolerable
doses of prostanoids administered via Hickman catheter and oral
therapy of endothelin receptor antagonists and phosphodiesterase
5 inhibitors. During that hospitalization the patient’s echocardi-
ography revealed dilated right heart with akinetic interventricular
septum, RVSP of 80 mm Hg, tricuspid annular plane systolic
excursion (TAPSE) of 11 mm, moderate tricuspid valve regurgi-
tation with annulus of 47 mm wide, as well as excessive fluid in the
pericardial sac. She also presented hepatosplenomegaly and sys-
tolic murmur over tricuspid valve. Biochemical tests pointed out
the significantly elevated NTproBNP (2208 ng/mL), impaired liver
function, and thrombopenia. Echocardiography performed at
admission for lung transplantation demonstrated findings similar
to those at qualification. Furthermore, function of the left heart
was also impaired (LVEF 46%). The patient underwent the pro-
cedure with intraoperative VA-ECMO. She was admitted to the
ICU with VA-ECMO support. Her early postoperative course was
complicated with bleeding, which required right re-thoracotomy
owing to hematoma of the pleural cavity. In following days, sup-
port was gradually weaned off according to daily echocardio-
graphic findings until explantation after 3 days. The patient was
sedated and mechanically ventilated during the postoperative
ECMO treatment. She regained the full mental capacity after a
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those observed in Patient 1. Her cardiac function was assessed
daily. Echocardiography performed 3 weeks after the procedure at
discharge demonstrated LVEF 50%, normokinesis with improved
movement of the interventricular septum, and trace of fluid in the
pericardial sac. Tricuspid regurgitation also subsided. She was
discharged in general good condition. She remains in our care,
and so far she has reached 12-month survival in good general
condition. Her late post-transplant course was complicated with
bronchial stenoses, which were treated with bronchoscopic in-
terventions. No bronchial stenting was needed.
Patient Number 3
A 40-year old man with advanced form of idiopathic pulmonary
arterial hypertension was treated with maximal tolerable doses of
endothelin receptor antagonists, prostanoids phosphodiesterase 5
inhibitors. Before admission to lung transplant facility, he was
hospitalized for several weeks owing to exacerbation of underly-
ing disease, which required catecholamines as part of the treat-
ment. At admission for lung transplantation, he presented
features of severe right heart failure, such as massive ascites,
edema of the lower extremities, and central cyanosis. Echocar-
diography performed the day before transplantation revealed
excessive fluid in the pericardial sac, generalized hypokinesis of
the left heart with LVEF 40% with RVSP 115 mm Hg, TAPSE
9, diameter of the tricuspid valve annulus 50 mm with central
massive regurgitation, and lack of cusps’ coaptation. AcT was 54
ms. Right ventricle ejection fraction was also severely impaired.
The patient underwent one complex procedure consisting of
tricuspid valve plasty using Carpentier-Edwards Classic ring 36
mm followed by double lung transplantation. It should be noted
that in order to perform such complex procedure cardiopulmo-
nary bypass circuit (CPB) was implemented into ECMO system,
which in this case was enriched with additional venous cannula
introduced through right jugular vein and connected with another
one coming from femoral vein. A day after the procedure the
patient was reoperated on because of significant postoperative
bleeding from right pleural cavity. It was the consequence of
right internal jugular vein dissection owing to improper percu-
taneuos introduction of ECMO inflow cannula. VA-ECMO was
maintained as a tool of heart conditioning for 6 days after the
operation. While on postoperative ECMO, the patient was me-
chanically ventilated and sedated. Weaning off VA-ECMO itself
was uneventful, as well as it was guided by daily echocardio-
graphic evaluation. However, after cessation of sedation the
patient presented symptoms of flaccid tetraplegia. Computed
tomography and magnetic resonance imaging assessment per-
formed 15 and 45 days after operation respectively, revealed
focal lesions of pons and cerebellum, as well as edema of the
spinal cord. His neurologic status only slightly improved despite
wide spectrum of pharmacologic treatment and extensive phys-
iotherapy. Routine echocardiographic examinations were per-
formed daily. Three weeks after the procedure his LVEF was
36%. General hypokinesis with akinesis of the interventricular
septum persisted, whereas the right ventricle had narrow, fissured
lumen with significant hypokinesis of the free wall. Severe
tricuspid valve regurgitation subsided into a trace. Coexisting
infections caused rapid deterioration of his state. He died 85
days after lung transplantation and 79 days after VA-ECMO
explantation. This case prompted authors to conduct so-called
“awake” ECMO after lung transplantation, aiming to avoid
neurologic complications and detect them early.Patient Number 4
A 20-year-old man with advanced idiopathic pulmonary arterial
hypertension was admitted in order to begin qualification process
for lung transplantation. Despite maximal tolerable doses of
intravenous prostanoid and oral forms of endothelin receptor
antagonists and phosphodiesterase 5 inhibitors, the patient pre-
sented symptoms of right heart failure such as ascites and central
cyanosis. Echocardiography revealed impaired function of the left
ventricle (LVEF 47%) with general hypokinesis and dyskinesis of
the interventricular septum. There was a trace of mitral valve
regurgitation, as well as massive central tricuspid valve regurgita-
tion with lack of cusps’ coaptation. Annulus of this valve was 50
mm. However, taking into consideration the patient’s height
(almost 200 cm), we did not consider performing valvuloplasty
during lung transpalntation. RVSP was 100 mm Hg, TAPSE 14
mm, and AcT 54 ms. A significant amount of excessive fluid was
depicted in the pericardial sac. Right ventricle was significantly
dilated, and its systolic function was defected. Owing to his height
it was difficult to find donor lungs. Almost a year after qualifica-
tion, the patient was admitted as a matching donor was available.
At admission, initial echocardiography the day before lung trans-
plantation did not differ much from the aforementioned one from
qualification. The patient was fully oxygen dependent and pre-
sented dyspnea at the slightest activity. The patient underwent
lung transplantation with VA-ECMO as the cardiorespiratory
support of choice. During the procedure, there was significant
blood loss owing to hypertrophic bronchial arteries and consid-
erable venous blood stasis. The patient was admitted to the ICU
with postoperative ECMO while sedated and mechanically venti-
lated but with intention of rapid implementation of “awake
ECMO protocol.” A few hours after admission to the ICU, the
patient regained consciousness almost immediately after cessation
of Propofol. He was extubated a few hours later. He was closely
monitored for the possibility of the Harlequin syndrome. In the
morning of the second day on VA-ECMO, it was noticeable that
oxygen saturation measured on the right hand showed several
short moments of desaturation. Immediate chest radiograph and
echocardiography revealed the beginning of the pulmonary edema
owing to acute mitral valve regurgitation as a result of the
widening of its annulus in course of increased preload of the left
ventricle. The patient was intubated again and treated accordingly.
His consciousness was maintained as small doses of dexmedeto-
midine were administered to facilitate the presence of the endo-
tracheal tube. During ECMO therapy daily neurologic and
echocardiographic checks were performed. Initial ECMO support
was 5.2 L/min, which was calculated to be the patient’s entire
cardiac output. After this event, it was decided to diminish this
parameter and to start intravenous infusion of adrenaline in small
doses. This decision led to subsiding mitral valve regurgitation, as
well as gradual increase of LVEF. Further weaning was carried
out under daily echocardiographic evaluation (twice a day) at the
average rate of 1 L/min during first day and 0.5 L/min in the
remaining days, and was uneventful (except one episode of
bleeding from the place of cannulation). VA-ECMO was explan-
ted 6 days after its introduction at support of 2 L/min without
complication and with satisfactory cardiac function. Three weeks
after transplantation, echocardiography evaluated left ventricle
function as satisfactory (LVEF 45%) with general normokinesis
and slight mitral regurgitation. Right heart function was also
assessed as satisfactory with RVSP of 30 mm Hg. Six weeks after
transplantation, the patient’s left ventricle systolic function is
proper (LVEF 51%), as well as reduction of tricuspid ring’s
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our original decision not to correct this valve (see above). Hick-
man catheter was removed 3 days prior to discharge, at which
point the patient presented good tolerance of exercise with no
symptoms of cardiac or respiratory dysfunction.DISCUSSION
Our findings are consistent with the work of Hannover,
Vienna, and Toronto centers and confirm that lung
transplant recipients owing to severe pulmonary primary
hypertension require intraoperative and postoperative pro-
longed VA-ECMO support [8e13]. An article published by
Wisser et al has already described its benefits among pa-
tients of the Lung Transplant Program of Vienna in 2001
[14]. Furthermore, the study published by Pereszlenyi et al
revealed that the Viennese way of ECMO support
concomitant with mechanical ventilation of fully sedated
patients has its benefits as well as risks [11]. Four out of 17
patients in their study required re-thoracotomy owing to
hemostatic complications of VA-ECMO. We recognized
that such problem also was present among our patients.
Available literature suggests that up to 50% of patients may
experience bleeding events, as well as a smaller percentage
might encounter some form of thrombosis [15,16]. Ac-
cording to those studies, targeting a specified activated
partial thromboplastin time plays a key role. An Austrian
study by Moser et al demonstrated that patients with pro-
longed VA-ECMO support after bilateral lung trans-
plantation benefit from such strategy in comparison to
those, who have ECMO explanted immediately after the
procedure [8]. Such finding is supported by a more recent
study from the same facility by Hoetzenecker et al [10]. Such
treatment provides excellent results with 1-year survival of
lung transplant recipients owing to severe pulmonary hy-
pertension exceeding 90%, as reported by Hoeper et al [12].
Austrian experience uses VA-ECMO as prolonged mean of
heart conditioning along with mechanical ventilation and
sedation. The first 3 patients of our work were also treated
this way. As it was described by the authors, certain
neurologic aspects of this treatment made us rethink our
postoperative ECMO strategy. The German lung transplant
facility of Hannover also emphasizes benefits of ECMO,
with notable differences being lack of sedation while on
ECMO and extubation as soon as possible [9,13]. Such
strategy allows for early detection of neurologic complica-
tions and does not burden the cerebral function with
adverse effects of long-time sedation. Patient number 4 was
treated this way with great outcome. Survival rates at 3 and
12 months of patients described by Tudorache et al were
100% and 96%, respectively [13]. Furthermore, other re-
sults published from the same German center revealed that
proper awake postoperative ECMO management among
patients with severe primary pulmonary hypertension pro-
duces 5-year survival rates comparable to recipients owing
to other underlying diseases [9]. The aforementioned study
by Salman et al also presents results suggesting that theirstrategy also favors achievement of normal cardiac function
after lung transplantation.
Tricuspid valve regurgitation among patients with severe
pulmonary hypertension can occur in the course of the
disease. Its severity correlates with severity of pulmonary
arterial hypertension, as well as it is a significant predictor of
long-term mortality [17]. Influence of lung transplantation
without tricuspid valve plasty on right ventricle function was
assessed by Gorter et al [18]. Right ventricular recovery was
confirmed by cardiac magnetic resonance imaging. Favor-
able changes in ejection fraction and muscle mass of both
ventricles were noted. The area of the tricuspid valve
annulus decreased significantly, as well as no patient expe-
rienced this valve regurgitation after lung transplantation.
This finding indicates that tricuspid valve plasty is not always
necessary among such patients. On the other hand, the
study by Shigemura et al assessed that combined tricuspid
valve plasty and bilateral lung transplantation were suc-
cessfully performed without an increase in morbidity or
mortality and contributed to decreased primary graft
dysfunction [19].CONCLUSION
This study describes the first Polish experience with
consecutive intra- and postoperative prolonged VA-ECMO
as a tool of heart conditioning. The first 3 patients were
managed in accordance with Viennese protocol (sedated
and mechanically ventilated during VA-ECMO). Owing to
neurologic complications, the fourth patient was treated
with awake ECMO protocol as led by Hannover’s example.
Lung transplant recipients owing to severe pulmonary
primary hypertension undeniably require intraoperative
and, what is of utmost importance, postoperative prolonged
VA-ECMO support, preferably as they are awake and
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